Table 2.

Baseline characteristics for patients with SIRI ≤ 0.85 versus SII>0.85 in primary and validation cohort.

Clinical parameter	Primary cohort				Validation cohort
	SIRI ≤ 0.85 (214)	SIRI > 0.85 (228)	χ2	P	SIRI ≤ 0.85 (90)	SIRI > 0.85 (62)	χ2	P
Sex			0.01	0.972			2.26	0.133
Male	143	152			72	43
Female	71	76			18	19
Age			2.18	0.140			0.403	0.699
≤60	140	164			55	42
>60	74	64			35	20
Tumor location			0.25	0.884			1.01	0.603
Upper	35	39			10	5
Middle	82	91			53	34
Lower	97	98			27	23
Histological grade			0.03	0.854			0.14	0.706
Well or moderately differentiated	94	111			55	36
Poorly or not differentiated	120	117			35	26
Lauren type			1.93	0.382			0.26	0.880
Diffuse	39	34			19	14
Intestinal	89	109			40	25
Mixed	86	85			31	23
Tumor size			0.01	0.907			0.03	0.855
≤5	88	95			42	28
>5	126	133			48	34
Lymphovascular invasion			0.12	0.729			0.01	0.968
No	158	165			54	37
Yes	56	63			36	25
Perineural invasion			0.96	0.326			0.02	0.890
No	130	128			60	42
Yes	130	128			30	20
TNM stage (AJCC, 8th)			30.85	<0.001*			15.10	0.001*
I	72	29			35	7
II	65	71			41	36
III	77	128			14	19
Adjuvant chemotherapy			0.06	0.800			0.18	0.670
No	87	90			35	22
Yes	127	138			55	40
NLR			26.363	<0.001*			22.12	<0.001*
NLR ≤ 1.32	133	86			41	6
NLR>1.32	81	142			49	56
PLR			18.194	<0.001*			13.984	<0.001*
PLR ≤ 128	99	61			61	23
PLR>128	115	167			29	39
MLR			25.93	<0.001*			42.93	<0.001*
MLR ≤ 0.24	140	94			81	25
MLR>0.24	74	134			9	37

*represents statistical significance.